The O
effects O
of O
N B
- I
nitro I
- I
L I
- I
arginine I
- I
methyl I
ester I
( O
L B
- I
NAME I
) O
a O
nitric B
oxide I
( O
NO B
) O
synthase O
inhibitor O
and O
L B
- I
arginine I
, O
a O
NO B
precursor O
, O
were O
investigated O
on O
lidocaine B
- O
induced O
convulsions O
. O

The O
analogs O
tested O
were O
: O
11 B
- I
ketopregnenolone I
sulphate I
( O
an O
agent O
that O
is O
inactive O
at O
GABA B
( O
A O
) O
Rs O
and O
NMDARs O
) O
, O
epipregnanolone B
( I
[ I
3beta I
- I
hydroxy I
- I
5beta I
- I
pregnan I
- I
20 I
- I
one I
] I
sulphate I
, O
an O
inhibitor O
of O
both O
GABA B
( O
A O
) O
Rs O
and O
NMDARs O
) O
, O
and O
a O
newly O
synthesized O
( O
- O
) O
PREGS B
enantiomer O
( O
which O
is O
identical O
to O
PREGS B
in O
effects O
on O
GABA B
( O
A O
) O
Rs O
and O
NMDARs O
) O
. O

( B
RS I
) I
- I
1 I
- I
aminoindan I
- I
1 I
, I
5 I
- I
dicarboxylic I
acid I
( O
AIDA B
; O
0 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
potent O
and O
selective O
mGluR1 O
antagonist O
, O
or O
( B
2R I
, I
4R I
) I
- I
4 I
- I
aminopyrrolidine I
- I
2 I
, I
4 I
- I
dicarboxylate I
( O
2R B
, I
4R I
- I
APDC I
; O
7 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
selective O
group O
II O
agonist O
, O
was O
injected O
bilaterally O
into O
the O
striatum O
of O
haloperidol B
- O
treated O

( B
RS I
) I
- I
1 I
- I
aminoindan I
- I
1 I
, I
5 I
- I
dicarboxylic I
acid I
( O
AIDA B
; O
0 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
potent O
and O
selective O
mGluR1 O
antagonist O
, O
or O
( B
2R I
, I
4R I
) I
- I
4 I
- I
aminopyrrolidine I
- I
2 I
, I
4 I
- I
dicarboxylate I
( O
2R B
, I
4R I
- I
APDC I
; O
7 O
. O
5 O
- O
15 O
microg O
/ O
0 O
. O
5 O
microl O
) O
, O
a O
selective O
group O
II O
agonist O
, O
was O
injected O
bilaterally O
into O
the O
striatum O
of O
haloperidol B
- O
treated O

Among O
several O
chemoconvulsants O
, O
bicuculline B
, O
N B
- I
methyl I
- I
D I
- I
aspartic I
acid I
and O
BAY B
k I
- I
8644 I
( O
the O
opener O
of O
L O
- O
type O
calcium B
channels O
) O
reversed O
the O
protective O
activity O
of O
loreclezole B
alone O
and O
its O
combination O
with O
valproate B
. O

A O
single O
dose O
of O
valproic B
acid I
( O
VPA B
) O
, O
which O
is O
a O
widely O
used O
antiepileptic O
drug O
, O
is O
associated O
with O
oxidative O
stress O
in O
rats O
, O
as O
recently O
demonstrated O
by O
elevated O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
isoprostane I
( O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
) O
. O

A O
single O
dose O
of O
valproic B
acid I
( O
VPA B
) O
, O
which O
is O
a O
widely O
used O
antiepileptic O
drug O
, O
is O
associated O
with O
oxidative O
stress O
in O
rats O
, O
as O
recently O
demonstrated O
by O
elevated O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
isoprostane I
( O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
) O
. O

Oxidative O
stress O
was O
assessed O
by O
determining O
plasma O
and O
liver O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
, O
lipid B
hydroperoxides I
( O
LPO B
) O
, O
and O
thiobarbituric B
acid I
reactive I
substances I
( O
TBARs B
) O
. O

Plasma O
and O
liver O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
were O
elevated O
and O
reached O
a O
plateau O
after O
day O
2 O
of O
VPA B
treatment O
compared O
to O
control O
. O

Overall O
, O
these O
findings O
indicate O
that O
VPA B
treatment O
results O
in O
oxidative O
stress O
, O
as O
measured O
by O
levels O
of O
15 B
- I
F I
( I
2t I
) I
- I
IsoP I
, O
which O
precedes O
the O
onset O
of O
necrosis O
, O
steatosis O
, O
and O
elevated O
levels O
of O
serum O
alpha O
- O
GST O
. O

Via O
the O
sequential O
isolation O
of O
Pueraria O
thunbergiana O
, O
the O
active O
component O
was O
ultimately O
identified O
as O
daidzein B
( O
4 B
' I
, I
7 I
- I
dihydroxy I
- I
isoflavone I
) O
. O

To O
begin O
addressing O
this O
need O
, O
we O
characterized O
UMB24 B
( O
1 B
- I
( I
2 I
- I
phenethyl I
) I
- I
4 I
- I
( I
2 I
- I
pyridyl I
) I
- I
piperazine I
) O
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
( O
3alpha B
- I
tropanyl I
- I
2 I
- I
( I
4 I
- I
chorophenoxy I
) I
butyrate I
) O
in O
receptor O
binding O
and O
behavioral O
studies O
. O

To O
begin O
addressing O
this O
need O
, O
we O
characterized O
UMB24 B
( O
1 B
- I
( I
2 I
- I
phenethyl I
) I
- I
4 I
- I
( I
2 I
- I
pyridyl I
) I
- I
piperazine I
) O
and O
( O
+ O
/ O
- O
) O
- O
SM B
21 I
( O
3alpha B
- I
tropanyl I
- I
2 I
- I
( I
4 I
- I
chorophenoxy I
) I
butyrate I
) O
in O
receptor O
binding O
and O
behavioral O
studies O
. O

METHODS O
AND O
RESULTS O
: O
In O
order O
to O
investigate O
whether O
the O
HAART O
component O
zidovudine B
( O
3 B
' I
- I
azido I
- I
2 I
' I
, I
3 I
' I
- I
deoxythymidine I
; O
AZT B
) O
triggers O
the O
Fas O
- O
dependent O
cell O
- O
death O
pathway O
and O
cause O
cytoskeletal O
disruption O
in O
a O
murine O
model O
of O
DCM O
, O
8 O
- O
week O
- O
old O
transgenic O
( O
expressing O
Fas O
ligand O
in O
the O
myocardium O
: O
FasL O
Tg O
) O
and O
non O
- O
transgenic O
( O
NTg O
) O
mice O
received O
water O
ad O
libitum O
containing O
different O
concentrations O

Moreover O
, O
M O
( O
3 O
) O
- O
muscarinic O
acetylcholine B
receptor O
( O
mAChR O
) O
antagonist O
4 B
- I
DAMP I
( O
4 B
- I
diphenylacetoxy I
- I
N I
- I
methylpiperidine I
- I
methiodide I
) O
partially O
abolished O
the O
beneficial O
effects O
of O
pilocarpine B
. O

The O
effects O
of O
N B
, I
N I
' I
- I
dibenzhydrylethane I
- I
1 I
, I
2 I
- I
diamine I
dihydrochloride I
( O
AMN082 B
) O
, O
the O
first O
selective O
allosteric O
activator O
of O
mGlu7 O
receptors O
, O
were O
thus O
tested O
in O
different O
rodent O
models O
of O
PD O
. O

The O
anaemia O
induced O
by O
3 B
' I
- I
azido I
- I
3 I
' I
dideoxythymidine I
( O
AZT B
) O
is O
poorly O
understood O
. O

The O
in O
vivo O
characterization O
of O
a O
dual O
adenosine B
A I
( I
2A I
) I
/ I
A I
( I
1 I
) I
receptor I
antagonist I
in O
several O
animal O
models O
of O
Parkinson O
' O
s O
disease O
is O
described O
. O

OBJECTIVE O
: O
To O
describe O
the O
incidence O
of O
haematological O
, O
renal O
, O
hepatic O
and O
gastrointestinal O
toxicities O
in O
tumour O
- O
bearing O
dogs O
receiving O
1 B
- I
( I
2 I
- I
chloroethyl I
) I
- I
3 I
- I
cyclohexyl I
- I
1 I
- I
nitrosourea I
( O
CCNU B
) O
. O

Nociceptive O
effects O
induced O
by O
intrathecal O
administration O
of O
prostaglandin B
D2 I
, I
E2 I
, I
or I
F2 I
alpha I
to O
conscious O
mice O
. O

The O
intradermal O
injection O
of O
mu O
( O
morphine B
, O
Tyr B
- I
D I
- I
Ala I
- I
Gly I
- I
NMe I
- I
Phe I
- I
Gly I
- I
ol I
and O
morphiceptin B
) O
, O
kappa O
( O
trans B
- I
3 I
, I
4 I
- I
dichloro I
- I
N I
- I
methyl I
- I
N I
[ I
2 I
- I
( I
1 I
- I
pyrrolidinyl I
) I
cyclohexyl I
] I
benzeneactemide I
) O
and O
delta O
( O
[ B
D I
- I
Pen2 I
. I
5 I
] I
- I
enkephalin I
and O
[ B
D I
- I
Ser2 I
] I
- I
[ I
Leu I
] I
enkephalin I
- I

The O
intradermal O
injection O
of O
mu O
( O
morphine B
, O
Tyr B
- I
D I
- I
Ala I
- I
Gly I
- I
NMe I
- I
Phe I
- I
Gly I
- I
ol I
and O
morphiceptin B
) O
, O
kappa O
( O
trans B
- I
3 I
, I
4 I
- I
dichloro I
- I
N I
- I
methyl I
- I
N I
[ I
2 I
- I
( I
1 I
- I
pyrrolidinyl I
) I
cyclohexyl I
] I
benzeneactemide I
) O
and O
delta O
( O
[ B
D I
- I
Pen2 I
. I
5 I
] I
- I
enkephalin I
and O
[ B
D I
- I
Ser2 I
] I
- I
[ I
Leu I
] I
enkephalin I
- I

The O
intradermal O
injection O
of O
mu O
( O
morphine B
, O
Tyr B
- I
D I
- I
Ala I
- I
Gly I
- I
NMe I
- I
Phe I
- I
Gly I
- I
ol I
and O
morphiceptin B
) O
, O
kappa O
( O
trans B
- I
3 I
, I
4 I
- I
dichloro I
- I
N I
- I
methyl I
- I
N I
[ I
2 I
- I
( I
1 I
- I
pyrrolidinyl I
) I
cyclohexyl I
] I
benzeneactemide I
) O
and O
delta O
( O
[ B
D I
- I
Pen2 I
. I
5 I
] I
- I
enkephalin I
and O
[ B
D I
- I
Ser2 I
] I
- I
[ I
Leu I
] I
enkephalin I
- I

Intradermal O
injection O
of O
mu O
, O
but O
not O
delta O
or O
kappa O
opioid O
- O
agonists O
, O
however O
, O
produced O
dose O
- O
dependent O
inhibition O
of O
prostaglandin B
E2 I
- O
induced O
hyperalgesia O
. O

Recent O
preclinical O
and O
clinical O
studies O
with O
the O
thymidylate O
synthase O
inhibitor O
N10 B
- I
propargyl I
- I
5 I
, I
8 I
- I
dideazafolic I
acid I
( O
CB B
3717 I
) O
. O

CB B
3717 I
, O
N10 B
- I
propargyl I
- I
5 I
, I
8 I
- I
dideazafolic I
acid I
, O
is O
a O
tight O
- O
binding O
inhibitor O
of O
thymidylate O
synthase O
( O
TS O
) O
whose O
cytotoxicity O
is O
mediated O
solely O
through O
the O
inhibition O
of O
this O
enzyme O
. O

Among O
various O
oral O
antiplatelets O
, O
a O
combination O
of O
a O
novel O
prostacyclin B
analogue O
beraprost B
( O
BPT B
) O
and O
a O
potent O
phosphodiesterase O
inhibitor O
cilostazol B
( O
CLZ B
) O
may O
result O
in O
untoward O
clinical O
effects O
due O
to O
possible O
synergistic O
elevation O
of O
intracellular O
cAMP B
( O
cyclic B
adenosine I
3 I
' I
, I
5 I
' I
- I
monophosphate I
) O
. O

Several O
structurally O
related O
metabolites O
of O
progesterone B
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
20 I
- I
ones I
) O
and O
deoxycorticosterone B
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
21 I
- I
diol I
- I
20 I
- I
ones I
) O
and O
their O
3 O
beta O
- O
epimers O
were O
evaluated O
for O
protective O
activity O
against O
pilocarpine B
- O
, O
kainic B
acid I
- O
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
- O
induced O
seizures O
in O
mice O
. O

Several O
structurally O
related O
metabolites O
of O
progesterone B
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
20 I
- I
ones I
) O
and O
deoxycorticosterone B
( O
3 B
alpha I
- I
hydroxy I
pregnane I
- I
21 I
- I
diol I
- I
20 I
- I
ones I
) O
and O
their O
3 O
beta O
- O
epimers O
were O
evaluated O
for O
protective O
activity O
against O
pilocarpine B
- O
, O
kainic B
acid I
- O
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
- O
induced O
seizures O
in O
mice O
. O

The O
therapeutic O
use O
of O
selective O
DA B
D1 O
receptor O
agonists O
such O
as O
SKF B
- I
82958 I
( O
6 B
- I
chloro I
- I
7 I
, I
8 I
- I
dihydroxy I
- I
3 I
- I
allyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzaze I
pine I
hydrobromide I
) O
and O
A B
- I
77636 I
( O
[ B
1R I
, I
3S I
] I
3 I
- I
[ I
1 I
' I
- I
admantyl I
] I
- I
1 I
- I
aminomethyl I
- I
3 I
, I
4 I
- I
dihydro I
- I
5 I
, I
6 I
- I

dihydroxy I
- I
1H I
- I
2 I
- I
benzo I
pyran I
hydrochloride I
) O
seems O
limited O
because O
of O
their O
duration O
of O
action O
, O
which O
is O
too O
short O
for O
SKF B
- I
82958 I
( O
< O
1 O
hr O
) O
and O
too O
long O
for O
A B
- I
77636 I
( O
> O
20 O
hr O
, O
leading O
to O
behavioral O
tolerance O
) O
. O

We O
therefore O
conducted O
the O
present O
acute O
dose O
- O
response O
study O
in O
four O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
- O
exposed O
cynomolgus O
monkeys O
primed O
to O
exhibit O
levodopa B
- O
induced O
dyskinesias O
to O
evaluate O
the O
locomotor O
and O
dyskinetic O
effects O
on O
challenge O
with O
four O
doses O
( O
from O
0 O
. O
03 O
to O
1 O
. O
0 O
mg O
/ O
kg O
) O
of O
A B
- I
86929 I
( O
[ B
- I
] I
- I
[ I
5aR I
, I
11bS I
] I
- I
4 I
, I
5 I
, I
5a I
, I
6 I
, I

7 I
, I
11b I
- I
hexahydro I
- I
2 I
- I
propyl I
- I
3 I
- I
thia I
- I
5 I
- I
+ I
+ I
+ I
azacyclopent I
- I
1 I
- I
ena I
[ I
c I
] I
phenathrene I
- I
9 I
- I
10 I
- I
diol I
) O
, O
a O
selective O
and O
full O
DA B
D1 O
- O
like O
receptor O
agonist O
with O
an O
intermediate O
duration O
of O
action O
. O

Levodopa B
and O
the O
DA B
D2 O
- O
like O
receptor O
agonist O
, O
LY B
- I
171555 I
( O
[ B
4aR I
- I
trans I
] I
- I
4 I
, I
4a I
, I
5 I
, I
6 I
, I
7 I
, I
8 I
, I
8a I
, I
9 I
- I
o I
- I
dihydro I
- I
5n I
- I
propyl I
- I
2H I
- I
pyrazo I
lo I
- I
3 I
- I
4 I
- I
quinoline I
hydrochloride I
) O
were O
also O
used O
for O
comparison O
. O

